A4

enables the formulation to be applied at the selected dose per area.

---

102. (amended) The method according to claim 66 for the treatment of inflammatory disease, dermatosis, kidney or liver failure, adrenal insufficiency, aspiration syndrome, Behcet syndrome, bites and stings, blood disorders, such as cold-haemagglutinin disease, haemolytic anemia, hypereosinophilia, hypoplastic anemia, macroglobulinaemia, trombocytopenic purpura, furthermore, for the management of bone disorders, cerebral oedema, Cogan's syndrome, congenital adrenal hyperplasia, connective tissue disorders, such as lichen, lupus erythematosus, polymyalgia rheumatica, polymyositis and dermatomyositis, epilepsy, eye disorders, such as cataracts, Graves' ophthalmopathy, haemangioma, herpes infections, neuropathies, retinal vasculitis, scleritis, for some gastro-intestinal disorders, such as inflammatory bowel disease, nausea and oesophageal damage, for hypercalcaemia, infections, e.g. of the eye (as in infections mononucleosis), for Kawasaki disease, myasthenia gravis, various pain syndromes, such as postherpetic neuralgia, for polyneuropathies, pancreatitis, in respiratory disorders, such as asthma, for the management of rheumatoid disease and osteoarthritis, rhinitis, sarcoidosis, skin diseases, such as alopecia, eczema, erythema multiforme, lichen, pemphigus and pemphigoid, psoriasis, pyoderma gangrenosum, urticaria, in case of thyroid and vascular disorders.

A5

---

**REMARKS**

For the sole purpose of reducing initial claims fees, and placing the claims in U.S.-style format, claims 10-34, 42-59, 62-65 and 70-101 have been cancelled without prejudice, claims 5-9, 35, 38, 39-41, 60 and 102 have been amended.

Applicants expressly reserve all rights to prosecute the subject matter of those cancelled and amended claims, either in the present application or suitable continuing application.

Early consideration and allowance of the application are earnestly solicited.

Respectfully submitted,

Peter F. Corless (Reg. 33,860)
EDWARDS & ANGELL, LLP
*Dike, Bronstein, Roberts & Cushman IP Group*
P.O. Box 9169
Boston, MA 02209
(617) 439-4444

**MARKED VERSION TO SHOW CHANGES**

5. (amended) The method of claim 2 wherein [according to any of claims 2, 3 or 4, characterised in that] said at least two substances differ by at least a factor of 10 in solubility in said polar liquid.

6. (amended) The method of claim 1 wherein [according to any of claims 1, 3, 4 or 5, characterised in that] said substances when in the form of homo-aggregates (for the more soluble substance) or of hetero-aggregates (for any combination of both said substances) have a preferred average diameter smaller than the diameter of homo-aggregates containing merely the less soluble substance.

7. (amended) The method of claim 1 wherein [according to any of claims 1, 2, 4, 5 or 6, characterised in that] the more soluble substance tends to solubilise the droplet and the content of such substance is to up to 99 mol-% of solubilising concentration or else corresponds to up to 99 mol-% of the saturating concentration in the unsolubilised droplet.

8. (amended) The method of claim 1 wherein [according to any of claims 1, 2, 3, 5, 6 or 7, characterised in that] the presence of the more soluble substance lowers the average elastic energy of the membrane-like coating to a value at least 5 times lower[, more preferably at least 10 times lower and most preferably more than 10 times lower,] than the average elastic energy of red blood cells or of phospholipid bilayers with fluid aliphatic chains.

9. (amended) The method of claim 1 wherein [according to any of the preceding claims, characterised in that] the flux across said barrier is increased by enlarging the applied dose per area of said penetrants.

35. (amended) A patch comprising a [, containing the] formulation of claim 1 [as

defined in anyone of the preceding claims,] in an amount corresponding to the desired dose per area.

38. (amended) The patch according to claim 36 wherein [claims 36 or 37, characterised in that] the non-occlusive backing liner exhibits a mean vapor transmission rate (MVTR) of more than 1000 g/m$^2$day[, preferably of more than 5.000 g/m$^2$day and most preferably of more than 10.000 g/m$^2$day].

39. (amended) The patch according to claim 38 wherein [any of claims 38 or 39, characterised in that] the penetrant flux across the barrier is controlled by the solvent disappearance across the non-occlusive backing liner.

40. (amended) The patch of claim 35 wherein [according to any of claims 35 to 39, characterised in that] the non-occlusive backing liner has pores of smaller than 100 nm, preferably smaller than 70 nm and most preferably of smaller than 30 nm.

41. (amended) The patch of claim 35 wherein [according to any of claims 35 to 40, characterised in that] the non-occlusive backing liner comprises a membrane [preferably] selected from the group comprising a polyurethane membrane, a polyester track-etched porous membrane, a polycarbonate track-etched porous membrane and a polyethylene microporous membrane.

60. (amended) A kit comprising [containing] a formulation of claim 1 [as in any of claims 1 to 34] in an amount which enables the formulation to be applied at the selected dose per area[, according to any of the preceding claims].

102. (amended) The method according to claim 66 [any of claims 66 to 73] for the treatment of inflammatory disease, dermatosis, kidney or liver failure, adrenal insufficiency, aspiration syndrome, Behcet syndrome, bites and stings, blood disorders, such as cold-haemagglutinin disease, haemolytic anemia, hypereosinophilia, hypoplastic anemia, macroglobulinaemia, trombocytopenic purpura, furthermore, for the management of bone disorders, cerebral oedema, Cogan's syndrome, congenital adrenal hyperplasia, connective tissue disorders, such as lichen, lupus erythematosus, polymyalgia rheumatica, polymyositis and dermatomyositis, epilepsy, eye disorders, such as cataracts, Graves' ophthalmopathy, haemangioma, herpes infections, neuropathies, retinal vasculitis, scleritis, for some gastro-intestinal disorders, such as inflammatory bowel disease, nausea and oesophageal damage, for hypercalcaemia, infections, e.g. of the eye (as in infections mononucleosis), for Kawasaki disease, myasthenia gravis, various pain syndromes, such as postherpetic neuralgia, for polyneuropathies, pancreatitis, in respiratory disorders, such as asthma, for the management of rheumatoid disease and osteoarthritis, rhinitis, sarcoidosis, skin diseases, such as alopecia, eczema, erythema multiforme, lichen, pemphigus and pemphigoid, psoriasis, pyoderma gangrenosum, urticaria, in case of thyroid and vascular disorders.